The Complex Clinical Picture of Side Effects to Biologicals

Medical Clinics of North America

Volumn 94, Issue 4, 2010, Pages 791-804

  Hausmann, Oliver V ^a   Seitz, Michael ^a   Villiger, Peter M ^a   Pichler, Werner J ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b ADR AC GmbH   (Switzerland)

Author keywords

Acute infusion reactions; Adverse side effects; Biological; Cytokine dysbalance syndrome; Hypersensitivity subclassifications; Monoclonal therapeutic antibodies

Indexed keywords

BIOLOGICAL PRODUCT; CETUXIMAB; MONOCLONAL ANTIBODY; TGN 1412; XENOBIOTIC AGENT;

ADVERSE DRUG REACTION; BIOLOGICAL THERAPY; CLINICAL CLASSIFICATION; CLINICAL FEATURE; CLINICAL TRIAL; CYTOKINE STORM; DRUG CROSS REACTIVITY; HUMAN; HYPERSENSITIVITY; IMMUNOGENICITY; IMMUNOLOGY; INJECTION SITE REACTION; PRIORITY JOURNAL; REVIEW;

ADULT; ALGORITHMS; ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL THERAPY; CROSS REACTIONS; CYTOKINES; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; IMMUNOGLOBULIN E; IMMUNOLOGIC FACTORS; TH1 CELLS; TH2 CELLS; XENOBIOTICS;

EID: 77953563408     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2010.03.001     Document Type: Review

References (68)

1. Pichler W.J. Adverse side effects to biological agents. Allergy 61 8 (2006) 912-920
2. Saxon A. Who-mab's on first and what-cept's on second. I don't know-third base. Clin Immunol 127 3 (2008) 267
3. Friedmann B. Commercial insight: top 20 cancer therapy brands-sales of targeted therapies overtake cytotoxics in 2006. A Datamonitor 2007. Product Code DMHC2299. 2007. Available at: http://www.datamonitor.com. Accessed March 9, 2010.
4. Abbas A.K., and Lichtman A.H. Cellular and molecular immunology. 6th edition (2009), Saunders, Philadelphia Accessed March 9, 2010
5. Desgeorges A., Gabay C., Silacci P., et al. Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid. J Rheumatol 24 8 (1997) 1510-1516
6. Vasquez E.M., Fabrega A.J., and Pollak R. OKT3-induced cytokine-release syndrome: occurrence beyond the second dose and association with rejection severity. Transplant Proc 27 1 (1995) 873-874
7. Suntharalingam G., Perry M.R., Ward S., et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355 10 (2006) 1018-1028
8. van der Kolk L.E., Grillo-Lopez A.J., Baars J.W., et al. Complement activation plays a key role in the side effects of rituximab treatment. Br J Haematol 115 4 (2001) 807-811
9. Raasveld M.H., Bemelman F.J., Schellekens P.T., et al. Complement activation during OKT3 treatment: a possible explanation for respiratory side effects. Kidney Int 43 5 (1993) 1140-1149
10. Lees C.W., Ali A.I., Thompson A.I., et al. The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. Aliment Pharmacol Ther 29 3 (2009) 286-297
11. Medeot M., Zaja F., Vianelli N., et al. Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results. Eur J Haematol 81 3 (2008) 165-169
12. Pilette C., Coppens N., Houssiau F.A., et al. Severe serum sickness-like syndrome after omalizumab therapy for asthma. J Allergy Clin Immunol 120 4 (2007) 972-973
13. Gamarra R.M., McGraw S.D., Drelichman V.S., et al. Serum sickness-like reactions in patients receiving intravenous infliximab. J Emerg Med 30 1 (2006) 41-44
14. Cheifetz A., Smedley M., Martin S., et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 98 6 (2003) 1315-1324
15. Arnold D.F., and Misbah S.A. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 358 25 (2008) 2735 [author reply: 2735-6]
16. Chung C.H., Mirakhur B., Chan E., et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 358 11 (2008) 1109-1117
17. Grims R.H., Kranke B., and Aberer W. Pitfalls in drug allergy skin testing: false-positive reactions due to (hidden) additives. Contact Dermatitis 54 5 (2006) 290-294
18. Steiner U.C., Gentinetta T., Hausmann O., et al. IgE-mediated anaphylaxis to intraarticular glucocorticoid preparations. AJR Am J Roentgenol 193 2 (2009) W156-157
19. Coors E.A., Seybold H., Merk H.F., et al. Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions. Ann Allergy Asthma Immunol 95 6 (2005) 593-599
20. Price K.S., and Hamilton R.G. Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy. Allergy Asthma Proc 28 3 (2007) 313-319
21. Steele R.H., Limaye S., Cleland B., et al. Hypersensitivity reactions to the polysorbate contained in recombinant erythropoietin and darbepoietin. Nephrology (Carlton) 10 3 (2005) 317-320
22. Lin W.L., Lin W.C., Yang J.Y., et al. Fatal toxic epidermal necrolysis associated with cetuximab in a patient with colon cancer. J Clin Oncol 26 16 (2008) 2779-2780
23. Fischer M., Fiedler E., Marsch W.C., et al. Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol 146 4 (2002) 707-709
24. Moneret-Vautrin D.A., Morisset M., Vignaud J.M., et al. T cell mediated allergy to abciximab. Allergy 57 3 (2002) 269-270
25. Benucci M., Manfredi M., Saviola G., et al. Correlation between atopy and hypersensitivity reactions during therapy with three different TNF-alpha blocking agents in rheumatoid arthritis. Clin Exp Rheumatol 27 2 (2009) 333-336
26. Clay H., Volkman H.E., and Ramakrishnan L. Tumor necrosis factor signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death. Immunity 29 2 (2008) 283-294
27. Abbas A.K., Murphy K.M., and Sher A. Functional diversity of helper T lymphocytes. Nature 383 6603 (1996) 787-793
28. Bennett A.N., Wong M., Zain A., et al. Adalimumab-induced asthma. Rheumatology (Oxford) 44 9 (2005) 1199-1200
29. Gonnet-Gracia C., Barnetche T., Richez C., et al. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers. Clin Exp Rheumatol 26 3 (2008) 401-407
30. Krause I., Valesini G., Scrivo R., et al. Autoimmune aspects of cytokine and anticytokine therapies. Am J Med 115 5 (2003) 390-397
31. Costa M.F., Said N.R., and Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 37 6 (2008) 381-387
32. Perez-Soler R., and Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?. J Clin Oncol 23 22 (2005) 5235-5246
33. Mueller H.L. Diagnosis and treatment of insect sensitivity. J Asthma Res 3 4 (1966) 331-333
34. Sands B.E., Anderson F.H., Bernstein C.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350 9 (2004) 876-885
35. Fidder H., Schnitzler F., Ferrante M., et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 58 4 (2009) 501-508
36. Schnitzler F., Fidder H., Ferrante M., et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 58 4 (2009) 492-500
37. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 23 (2005) 2462-2476
38. Maini R., St Clair E.W., Breedveld F., et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT study group. Lancet 354 9194 (1999) 1932-1939
39. Prupas M. Reactions to infliximab in patients with rheumatoid arthritis. J Rheumatol 32 7 (2005) 1411 [author reply: 1411]
40. Kemp S.F., Lockey R.F., and Simons F.E. Epinephrine: the drug of choice for anaphylaxis. A statement of the World Allergy Organization. Allergy 63 8 (2008) 1061-1070
41. Sany J., Kaiser M.J., Jorgensen C., et al. Study of the tolerance of infliximab infusions with or without betamethasone premedication in patients with active rheumatoid arthritis. Ann Rheum Dis 64 11 (2005) 1647-1649
42. Tramer M.R., von Elm E., Loubeyre P., et al. Pharmacological prevention of serious anaphylactic reactions due to iodinated contrast media: systematic review. BMJ 333 7570 (2006) 675
43. Lenz H.J. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 12 5 (2007) 601-609
44. Chung C.H. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist 13 6 (2008) 725-732
45. Augustsson J., Eksborg S., Ernestam S., et al. Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 66 11 (2007) 1462-1466
46. Wasserman M.J., Weber D.A., Guthrie J.A., et al. Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number. J Rheumatol 31 10 (2004) 1912-1917
47. Ricart E., Panaccione R., Loftus E.V., et al. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 96 3 (2001) 722-729
48. Farrell R.J., Alsahli M., Jeen Y.T., et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 124 4 (2003) 917-924
49. Lequerre T., Vittecoq O., Klemmer N., et al. Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from an immunotherapy unit of rheumatology. J Rheumatol 33 7 (2006) 1307-1314
50. Borer-Reinhold M., Haeberli G., Bitzenhofer M., et al. A definite increase of serum tryptase within normal limits indicates a systemic allergic reaction. [abstract 14]. Abstracts of the XXVIII EAACI Congress of the European Academy of Allergy and Clinical Immunology, Warszawa, Poland, 6-10 June 2009. Allergy 64 Suppl 90 (2009) 7
51. Puchner T.C., Kugathasan S., Kelly K.J., et al. Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction. Inflamm Bowel Dis 7 1 (2001) 34-37
52. Lelong J., Duburque C., Fournier C., et al. [Desensitisation to infliximab in patients with Crohn's disease]. Rev Mal Respir 22 2 Pt 1 (2005) 239-246 [in French]
53. Duburque C., Lelong J., Iacob R., et al. Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions. Aliment Pharmacol Ther 24 5 (2006) 851-858
54. Jerath M.R., Kwan M., Kannarkat M., et al. A desensitization protocol for the mAb cetuximab. J Allergy Clin Immunol 123 1 (2009) 260-262
55. Brennan P.J., Rodriguez Bouza T., Hsu F.I., et al. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol 124 6 (2009) 1259-1266
56. Hanauer S.B., Wagner C.L., Bala M., et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2 7 (2004) 542-553
57. Kavanaugh A., Cush J., and Clair E.S. Anti-TNF-alpha monoclonal antibody (mAb) treatment of rheumatoid arthritis (RA) patients with active disease on methotrexate (MTX): results of open label, repeated dose administration following a single dose double-blind, placebo controlled trial. [abstract]. Arthritis Rheum 39 Suppl 9 (1996) 1296
58. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 9317 (2002) 1541-1549
59. Baert F., Noman M., Vermeire S., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348 7 (2003) 601-608
60. Sandborn W.J. Preventing antibodies to infliximab in patients with Crohn's disease: optimize not immunize. Gastroenterology 124 4 (2003) 1140-1145
61. Vermeire S., Noman M., Van Assche G., et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 56 9 (2007) 1226-1231
62. Dore R.K., Mathews S., Schechtman J., et al. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol 25 1 (2007) 40-46
63. Weinblatt M.E., Keystone E.C., Furst D.E., et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48 1 (2003) 35-45
64. Vila A.T., Puig L., Fernandez-Figueras M.T., et al. Adverse cutaneous reactions to anakinra in patients with rheumatoid arthritis: clinicopathological study of five patients. Br J Dermatol 153 2 (2005) 417-423
65. Zeltser R., Valle L., Tanck C., et al. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein. Arch Dermatol 137 7 (2001) 893-899
66. Winfield H., Lain E., Horn T., et al. Eosinophilic cellulitis-like reaction to subcutaneous etanercept injection. Arch Dermatol 142 2 (2006) 218-220
67. Benucci M., Manfredi M., Demoly P., et al. Injection site reactions to TNF-alpha blocking agents with positive skin tests. Allergy 63 1 (2008) 138-139
68. Severino M., Bonadonna P., and Passalacqua G. Large local reactions from stinging insects: from epidemiology to management. Curr Opin Allergy Clin Immunol 9 4 (2009) 334-337